nodes	percent_of_prediction	percent_of_DWPC	metapath
L-Arginine—NOS2—psoriatic arthritis	0.726	1	CbGaD
L-Arginine—NOS2—Dexamethasone—psoriatic arthritis	0.261	1	CbGbCtD
L-Arginine—L-Citrulline—NOS2—psoriatic arthritis	0.00187	1	CrCbGaD
L-Arginine—NOS2—IL23-mediated signaling events—IL23R—psoriatic arthritis	0.000548	0.168	CbGpPWpGaD
L-Arginine—NOS2—IL23-mediated signaling events—IL23A—psoriatic arthritis	0.000466	0.143	CbGpPWpGaD
L-Arginine—Skin necrosis—Methotrexate—psoriatic arthritis	0.000377	0.0441	CcSEcCtD
L-Arginine—Haematuria—Auranofin—psoriatic arthritis	0.000363	0.0425	CcSEcCtD
L-Arginine—NOS2—ATF-2 transcription factor network—IL23A—psoriatic arthritis	0.000321	0.0982	CbGpPWpGaD
L-Arginine—NOS3—Effects of Nitric Oxide—NOS2—psoriatic arthritis	0.000301	0.092	CbGpPWpGaD
L-Arginine—NOS3—ACE Inhibitor Pathway—ACE—psoriatic arthritis	0.000284	0.087	CbGpPWpGaD
L-Arginine—Necrosis—Methylprednisolone—psoriatic arthritis	0.000254	0.0297	CcSEcCtD
L-Arginine—Anorexia—Auranofin—psoriatic arthritis	0.000232	0.0271	CcSEcCtD
L-Arginine—Necrosis—Betamethasone—psoriatic arthritis	0.000231	0.027	CcSEcCtD
L-Arginine—Necrosis—Dexamethasone—psoriatic arthritis	0.000231	0.027	CcSEcCtD
L-Arginine—NOS2—IL23-mediated signaling events—IL17A—psoriatic arthritis	0.000218	0.0668	CbGpPWpGaD
L-Arginine—Decreased appetite—Auranofin—psoriatic arthritis	0.000211	0.0247	CcSEcCtD
L-Arginine—Extravasation—Dexamethasone—psoriatic arthritis	0.000208	0.0243	CcSEcCtD
L-Arginine—Extravasation—Betamethasone—psoriatic arthritis	0.000208	0.0243	CcSEcCtD
L-Arginine—NOS2—IL23-mediated signaling events—IL12B—psoriatic arthritis	0.000203	0.0621	CbGpPWpGaD
L-Arginine—Necrosis—Prednisone—psoriatic arthritis	0.000201	0.0235	CcSEcCtD
L-Arginine—Skin exfoliation—Triamcinolone—psoriatic arthritis	0.000191	0.0223	CcSEcCtD
L-Arginine—Skin exfoliation—Methylprednisolone—psoriatic arthritis	0.00019	0.0222	CcSEcCtD
L-Arginine—Skin exfoliation—Dexamethasone—psoriatic arthritis	0.000173	0.0202	CcSEcCtD
L-Arginine—Skin exfoliation—Betamethasone—psoriatic arthritis	0.000173	0.0202	CcSEcCtD
L-Arginine—Necrosis—Methotrexate—psoriatic arthritis	0.000168	0.0196	CcSEcCtD
L-Arginine—Vomiting—Auranofin—psoriatic arthritis	0.000154	0.0181	CcSEcCtD
L-Arginine—Rash—Auranofin—psoriatic arthritis	0.000153	0.0179	CcSEcCtD
L-Arginine—Dermatitis—Auranofin—psoriatic arthritis	0.000153	0.0179	CcSEcCtD
L-Arginine—Extravasation—Methotrexate—psoriatic arthritis	0.000151	0.0177	CcSEcCtD
L-Arginine—Skin exfoliation—Prednisone—psoriatic arthritis	0.000151	0.0176	CcSEcCtD
L-Arginine—Nausea—Auranofin—psoriatic arthritis	0.000144	0.0169	CcSEcCtD
L-Arginine—NOS2—Type II interferon signaling (IFNG)—HLA-B—psoriatic arthritis	0.000141	0.0432	CbGpPWpGaD
L-Arginine—NOS2—IL12-mediated signaling events—IL12B—psoriatic arthritis	0.000138	0.0422	CbGpPWpGaD
L-Arginine—Lethargy—Betamethasone—psoriatic arthritis	0.000134	0.0157	CcSEcCtD
L-Arginine—Lethargy—Dexamethasone—psoriatic arthritis	0.000134	0.0157	CcSEcCtD
L-Arginine—Skin exfoliation—Methotrexate—psoriatic arthritis	0.000126	0.0147	CcSEcCtD
L-Arginine—NOS3—Nitric oxide stimulates guanylate cyclase—NOS2—psoriatic arthritis	0.000125	0.0382	CbGpPWpGaD
L-Arginine—Lethargy—Prednisone—psoriatic arthritis	0.000117	0.0137	CcSEcCtD
L-Arginine—NOS3—Leptin signaling pathway—REL—psoriatic arthritis	0.000114	0.035	CbGpPWpGaD
L-Arginine—Sweating—Methylprednisolone—psoriatic arthritis	0.000107	0.0125	CcSEcCtD
L-Arginine—Lethargy—Methotrexate—psoriatic arthritis	9.77e-05	0.0114	CcSEcCtD
L-Arginine—NOS3—Latent infection of Homo sapiens with Mycobacterium tuberculosis—NOS2—psoriatic arthritis	9.45e-05	0.0289	CbGpPWpGaD
L-Arginine—NOS2—IL12-mediated signaling events—HLA-DRB1—psoriatic arthritis	8.12e-05	0.0248	CbGpPWpGaD
L-Arginine—Anaphylactic shock—Prednisolone—psoriatic arthritis	7.75e-05	0.00905	CcSEcCtD
L-Arginine—Tachycardia—Prednisolone—psoriatic arthritis	7.56e-05	0.00884	CcSEcCtD
L-Arginine—Hyperhidrosis—Prednisolone—psoriatic arthritis	7.49e-05	0.00875	CcSEcCtD
L-Arginine—Flushing—Prednisone—psoriatic arthritis	7.35e-05	0.0086	CcSEcCtD
L-Arginine—Anaphylactic shock—Triamcinolone—psoriatic arthritis	7.12e-05	0.00833	CcSEcCtD
L-Arginine—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	7.11e-05	0.00831	CcSEcCtD
L-Arginine—Sweating—Methotrexate—psoriatic arthritis	7.07e-05	0.00827	CcSEcCtD
L-Arginine—Haematuria—Methotrexate—psoriatic arthritis	7.03e-05	0.00822	CcSEcCtD
L-Arginine—Tachycardia—Triamcinolone—psoriatic arthritis	6.95e-05	0.00813	CcSEcCtD
L-Arginine—Tachycardia—Methylprednisolone—psoriatic arthritis	6.94e-05	0.00811	CcSEcCtD
L-Arginine—Hyperhidrosis—Triamcinolone—psoriatic arthritis	6.89e-05	0.00805	CcSEcCtD
L-Arginine—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	6.87e-05	0.00803	CcSEcCtD
L-Arginine—Anaphylactic shock—Dexamethasone—psoriatic arthritis	6.46e-05	0.00756	CcSEcCtD
L-Arginine—Anaphylactic shock—Betamethasone—psoriatic arthritis	6.46e-05	0.00756	CcSEcCtD
L-Arginine—Tachycardia—Dexamethasone—psoriatic arthritis	6.31e-05	0.00737	CcSEcCtD
L-Arginine—Tachycardia—Betamethasone—psoriatic arthritis	6.31e-05	0.00737	CcSEcCtD
L-Arginine—Hyperhidrosis—Betamethasone—psoriatic arthritis	6.25e-05	0.0073	CcSEcCtD
L-Arginine—Hyperhidrosis—Dexamethasone—psoriatic arthritis	6.25e-05	0.0073	CcSEcCtD
L-Arginine—Anorexia—Dexamethasone—psoriatic arthritis	6.16e-05	0.0072	CcSEcCtD
L-Arginine—Anorexia—Betamethasone—psoriatic arthritis	6.16e-05	0.0072	CcSEcCtD
L-Arginine—Hypersensitivity—Prednisolone—psoriatic arthritis	5.71e-05	0.00667	CcSEcCtD
L-Arginine—NOS2—IL23-mediated signaling events—TNF—psoriatic arthritis	5.65e-05	0.0173	CbGpPWpGaD
L-Arginine—Anaphylactic shock—Prednisone—psoriatic arthritis	5.63e-05	0.00658	CcSEcCtD
L-Arginine—Decreased appetite—Betamethasone—psoriatic arthritis	5.62e-05	0.00657	CcSEcCtD
L-Arginine—Decreased appetite—Dexamethasone—psoriatic arthritis	5.62e-05	0.00657	CcSEcCtD
L-Arginine—NOS3—AGE/RAGE pathway—NOS2—psoriatic arthritis	5.56e-05	0.017	CbGpPWpGaD
L-Arginine—Tachycardia—Prednisone—psoriatic arthritis	5.49e-05	0.00642	CcSEcCtD
L-Arginine—Hyperhidrosis—Prednisone—psoriatic arthritis	5.44e-05	0.00636	CcSEcCtD
L-Arginine—Anorexia—Prednisone—psoriatic arthritis	5.37e-05	0.00627	CcSEcCtD
L-Arginine—Hypersensitivity—Triamcinolone—psoriatic arthritis	5.25e-05	0.00614	CcSEcCtD
L-Arginine—Hypersensitivity—Methylprednisolone—psoriatic arthritis	5.24e-05	0.00612	CcSEcCtD
L-Arginine—Decreased appetite—Prednisone—psoriatic arthritis	4.89e-05	0.00572	CcSEcCtD
L-Arginine—Rash—Prednisolone—psoriatic arthritis	4.88e-05	0.00571	CcSEcCtD
L-Arginine—Dermatitis—Prednisolone—psoriatic arthritis	4.88e-05	0.0057	CcSEcCtD
L-Arginine—NOS3—Platelet homeostasis—NOS2—psoriatic arthritis	4.86e-05	0.0149	CbGpPWpGaD
L-Arginine—Headache—Prednisolone—psoriatic arthritis	4.85e-05	0.00567	CcSEcCtD
L-Arginine—Anaphylactic shock—Methotrexate—psoriatic arthritis	4.7e-05	0.0055	CcSEcCtD
L-Arginine—Nausea—Prednisolone—psoriatic arthritis	4.6e-05	0.00538	CcSEcCtD
L-Arginine—Hyperhidrosis—Methotrexate—psoriatic arthritis	4.55e-05	0.00532	CcSEcCtD
L-Arginine—Vomiting—Triamcinolone—psoriatic arthritis	4.53e-05	0.00529	CcSEcCtD
L-Arginine—Vomiting—Methylprednisolone—psoriatic arthritis	4.52e-05	0.00528	CcSEcCtD
L-Arginine—Rash—Triamcinolone—psoriatic arthritis	4.49e-05	0.00525	CcSEcCtD
L-Arginine—Dermatitis—Triamcinolone—psoriatic arthritis	4.49e-05	0.00525	CcSEcCtD
L-Arginine—Anorexia—Methotrexate—psoriatic arthritis	4.48e-05	0.00524	CcSEcCtD
L-Arginine—Rash—Methylprednisolone—psoriatic arthritis	4.48e-05	0.00524	CcSEcCtD
L-Arginine—Dermatitis—Methylprednisolone—psoriatic arthritis	4.48e-05	0.00523	CcSEcCtD
L-Arginine—Headache—Triamcinolone—psoriatic arthritis	4.46e-05	0.00522	CcSEcCtD
L-Arginine—Headache—Methylprednisolone—psoriatic arthritis	4.45e-05	0.0052	CcSEcCtD
L-Arginine—Nausea—Triamcinolone—psoriatic arthritis	4.23e-05	0.00495	CcSEcCtD
L-Arginine—Nausea—Methylprednisolone—psoriatic arthritis	4.22e-05	0.00494	CcSEcCtD
L-Arginine—Hypersensitivity—Prednisone—psoriatic arthritis	4.15e-05	0.00485	CcSEcCtD
L-Arginine—Vomiting—Betamethasone—psoriatic arthritis	4.11e-05	0.0048	CcSEcCtD
L-Arginine—Vomiting—Dexamethasone—psoriatic arthritis	4.11e-05	0.0048	CcSEcCtD
L-Arginine—Decreased appetite—Methotrexate—psoriatic arthritis	4.09e-05	0.00478	CcSEcCtD
L-Arginine—Rash—Dexamethasone—psoriatic arthritis	4.08e-05	0.00476	CcSEcCtD
L-Arginine—Rash—Betamethasone—psoriatic arthritis	4.08e-05	0.00476	CcSEcCtD
L-Arginine—Dermatitis—Betamethasone—psoriatic arthritis	4.07e-05	0.00476	CcSEcCtD
L-Arginine—Dermatitis—Dexamethasone—psoriatic arthritis	4.07e-05	0.00476	CcSEcCtD
L-Arginine—Headache—Dexamethasone—psoriatic arthritis	4.05e-05	0.00473	CcSEcCtD
L-Arginine—Headache—Betamethasone—psoriatic arthritis	4.05e-05	0.00473	CcSEcCtD
L-Arginine—Nausea—Betamethasone—psoriatic arthritis	3.84e-05	0.00449	CcSEcCtD
L-Arginine—Nausea—Dexamethasone—psoriatic arthritis	3.84e-05	0.00449	CcSEcCtD
L-Arginine—Vomiting—Prednisone—psoriatic arthritis	3.58e-05	0.00418	CcSEcCtD
L-Arginine—Rash—Prednisone—psoriatic arthritis	3.55e-05	0.00415	CcSEcCtD
L-Arginine—Dermatitis—Prednisone—psoriatic arthritis	3.55e-05	0.00414	CcSEcCtD
L-Arginine—Headache—Prednisone—psoriatic arthritis	3.53e-05	0.00412	CcSEcCtD
L-Arginine—Hypersensitivity—Methotrexate—psoriatic arthritis	3.47e-05	0.00405	CcSEcCtD
L-Arginine—NOS3—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriatic arthritis	3.45e-05	0.0105	CbGpPWpGaD
L-Arginine—Nausea—Prednisone—psoriatic arthritis	3.34e-05	0.00391	CcSEcCtD
L-Arginine—Vomiting—Methotrexate—psoriatic arthritis	2.99e-05	0.0035	CcSEcCtD
L-Arginine—Rash—Methotrexate—psoriatic arthritis	2.97e-05	0.00347	CcSEcCtD
L-Arginine—Dermatitis—Methotrexate—psoriatic arthritis	2.96e-05	0.00346	CcSEcCtD
L-Arginine—Headache—Methotrexate—psoriatic arthritis	2.95e-05	0.00344	CcSEcCtD
L-Arginine—Nausea—Methotrexate—psoriatic arthritis	2.79e-05	0.00327	CcSEcCtD
L-Arginine—NOS2—Spinal Cord Injury—TNF—psoriatic arthritis	2.23e-05	0.00683	CbGpPWpGaD
L-Arginine—NOS3—Hemostasis—NOS2—psoriatic arthritis	1.09e-05	0.00333	CbGpPWpGaD
L-Arginine—NOS3—Disease—NOS2—psoriatic arthritis	5.28e-06	0.00161	CbGpPWpGaD
